UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): ~~January~~March 261, 2013

PolyMedix, Inc.

(Exact Name of ~~Issuer~~Registrant as Specified in Charter)


Delaware	000-51895	27-0125925
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification Number)


170 N. Radnor-Chester Road; Suite 300 Radnor, Pennsylvania		19087
(Address of Principal Executive Offices)		(Zip Code)

(484) 598-2400

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Item 51.~~02.~~01 Entry ~~Departure~~into ofa ~~Directors~~Material orDefinitive ~~Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Agreement.

On ~~January~~March 301, 2013, ~~Nicholas~~PolyMedix, ~~Landekic’s~~Inc., ~~employment~~a asDelaware ~~president~~corporation (the “Company”) and ~~chief~~the ~~executive~~Company’s ~~officer~~wholly ofowned subsidiary, PolyMedix Pharmaceuticals, Inc. (collectively, ~~referred~~the to“Borrowers”), asentered into a Letter Agreement (the “~~company,~~Letter Agreement”) ~~ceased~~with MidCap Financial SBIC, LP, a Delaware limited partnership, as administrative agent and lender (the “Agent”). ~~Also~~ As previously reported, the Borrowers entered into a Second Amendment to Loan and Security Agreement (the “Second Amendment”) with Agent on January 3016, 2013,. The ~~the~~Letter ~~board~~Agreement, ofamong ~~directors~~other ofthings, extended the ~~company~~Fundraising ~~appointed~~Period ~~Edward~~and F.the ~~Smith~~Fundraising Termination Date (as ~~acting~~such ~~president~~terms ~~and~~are ~~chief~~defined ~~executive~~in ~~officer~~the Second Amendment) from March 2, 2013 to April 1, 2013. ~~Mr.~~ ~~Landekic~~The ~~had~~foregoing ~~functioned~~description asof the ~~principal~~Letter ~~executive~~Agreement ~~and~~is ~~operating~~qualified ~~officer~~in its entirety by reference to the full text of the ~~company~~Letter ~~and~~Agreement, ~~with~~which ~~his~~is ~~appointment~~filed as ~~acting~~Exhibit 10.1 ~~president~~to ~~and~~this ~~chief~~Current ~~executive~~Report ~~officer,~~on ~~Mr.~~Form ~~Smith~~8-K ~~will~~and ~~add~~incorporated ~~those~~herein ~~functions~~by toreference. The ~~his~~Second ~~existing~~Amendment ~~functions~~is filed as ~~principal~~Exhibit 10.2 ~~financial~~to ~~and~~this ~~accounting~~Current ~~officer~~Report on Form 8-K.

~~Edward~~Item F2.02 Results ~~Smith, age 41, has served as Vice President, Finance, Chief Financial Officer and Secretary~~ of ~~PolyMedix,~~Operations ~~Inc. since January 2006. Mr. Smith has approximately twenty years of combined biopharmaceutical industry~~ and ~~financial~~Financial ~~management experience~~Condition. From 2000 to 2005, he was Executive Director of Finance at InKine Pharmaceutical Company, Inc. (acquired by Salix Pharmaceuticals, Ltd. in 2005). From 1993 to 1999, Mr. Smith held various positions of increasing responsibility in public accounting, most recently at Deloitte & Touche LLP. Mr. Smith is licensed as a Certified Public Accountant in Pennsylvania and holds a B.S. degree in Business Administration from the University of Hartford.

On ~~January~~March 266, 2013, ~~the~~PolyMedix, ~~compensation~~Inc. ~~committee~~issued ofa ~~the~~press ~~company’s~~release ~~board~~announcing ofits ~~directors~~financial ~~modified~~results for the ~~terms~~year ofended ~~Mr.~~December ~~Landekic’s~~31, ~~employment~~2012. ~~arrangement~~A bycopy ~~reducing~~of ~~his~~the ~~base~~press ~~salary~~release tois ~~the~~furnished ~~rate~~herewith ofas ~~$250,000~~Exhibit ~~per~~99.1 ~~year,~~to ~~the~~this ~~minimum~~Current ~~amount~~Report ~~contemplated~~on ~~under~~Form ~~his~~8-K ~~employment~~and ~~agreement~~is ~~dated~~incorporated ~~July~~herein ~~30,~~by ~~2002~~reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed or furnished with this Current Report on Form 8-K.

Exhibit No. Description

10.1	Letter Agreement, dated March 1, 2013, by and among PolyMedix, Inc., PolyMedix Pharmaceuticals, Inc. and MidCap Financial SBIC, LP.

10.2	Second Amendment to Loan and Security Agreement, dated January 16, 2013, by and among PolyMedix, Inc., PolyMedix Pharmaceuticals, Inc., MidCap Financial SBIC, LP, as Agent for the Lenders and the other Lenders party thereto.

99.1 Press Release dated March 6, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	~~POLYMEDIX, INC.~~	POLYMEDIX, INC.
Date: January 30, 2013	By:	/s/ Edward F. Smith
Date: March 6, 2013		By:	/s/ Edward F. Smith
		Edward F. Smith
			Edward F. Smith President, Chief Executive Officer, Chief Financial Officer & Secretary
		Acting Chief Executive Officer
		and Chief Financial Officer

EXHIBIT INDEX


10.1	Letter Agreement, dated March 1, 2013, by and among PolyMedix, Inc., PolyMedix Pharmaceuticals, Inc. and MidCap Financial SBIC, LP.

10.2	Second Amendment to Loan and Security Agreement, dated January 16, 2013, by and among PolyMedix, Inc., PolyMedix Pharmaceuticals, Inc., MidCap Financial SBIC, LP, as Agent for the Lenders and the other Lenders party thereto.

99.1	Press Release dated March 6, 2013.

Filing Compare · POLYMEDIX, INC